Comparison between Oncotype DX test and standard prognostic criteria in estrogen receptor positive early-stage breast cancer Comparação entre o teste Oncotype DX e critérios prognósticos padronizados em câncer de mama receptor de estrogênio positivo em estágio inicial
نویسندگان
چکیده
Objective: To compare the prognosis estimated by standard prognostic criteria versus the prognosis estimated by the Oncotype DX. Methods: A retrospective study was performed on 22 patients with positive estrogen receptor, early-stage breast cancer who had an Oncotype DX recurrence score available. Results: Kappa value between Oncotype DX and standard prognostic criteria was: Adjuvant! (K = 0.091), Adjuvant! (Transbig) (K = 0.182) and National Comprehensive Cancer Network (K = 0.091). The Fisher’s exact test did not show correlation between Oncotype and standard prognostic criteria. Conclusion: Standard prognostic criteria showed no correlation with Oncotype DX.
منابع مشابه
Association Between Oncotype DX Recurrence Score and Clinicopathological Variables in Breast Cancer Patients
Introduction: Breast cancer is the most common cancer and the leading cause of cancer-related death in women. Clinicopathological variables are important factors in deciding on breast cancer treatment. This study evaluated the association between the recurrence score generated by the Oncotype DX® 21-gene assay and classic clinicopathological variables. Methods: A single-institution retrospect...
متن کاملRapid Health Technology Assessment of Oncotype DX in Patients with Early-Stage Breast Cancer
Introduction: Breast cancer is the most common cancer in women. Patients are treated with chemotherapy initially, and if not chemically treated, the risk of recurrence of the disease increases yearly. Therefore, methods for identifying patients for whom chemotherapy would be most beneficial are very important. The Oncotype DX test is a prognostic assay that predicts the likelihood of breast can...
متن کاملSpotlight on the utility of the Oncotype DX® breast cancer assay
The Oncotype DX® assay was developed to address the need for optimizing the selection of adjuvant systemic therapy for patients with estrogen receptor (ER)-positive, lymph node-negative breast cancer. It has ushered in the era of genomic-based personalized cancer care for ER-positive primary breast cancer and is now widely utilized in various parts of the world. Together with several other geno...
متن کاملGene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
UNLABELLED In February 2010, the Medical Advisory Secretariat (MAS) began work on evidence-based reviews of published literature surrounding three pharmacogenomic tests. This project came about when Cancer Care Ontario (CCO) asked MAS to provide evidence-based analyses on the effectiveness and cost-effectiveness of three oncology pharmacogenomic tests currently in use in Ontario.Evidence-based ...
متن کاملRelevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score.
OBJECTIVE/BACKGROUND Progesterone-receptor negativity (PR-) is predictive of adverse outcomes in estrogen receptor-positive (ER+) breast cancer. The Oncotype DX assay provides risk stratification for hormone receptor-positive (HR+) invasive breast cancer; however, the association of PR status and Oncotype DX recurrence scores (RSs) is less clear. METHODS We designed an analysis to determine w...
متن کامل